title: Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia.
abstract: OBJECTIVE
  To report the anatomic and functional outcomes of intravitreal ranibizumab in idiopathic parafoveal telangiectasia (IPT).
  
  
  METHODS
  Four eyes of three patients were included in this interventional case series. One patient (two eyes) had bilateral IPT (type 2) and two patients (two eyes) had unilateral (type 1) IPT. Retreatment was scheduled in case of leakage persistence in combination with visual acuity (VA) deterioration. Fluorescein angiography and optical coherence tomography were performed together with a full ophthalmic examination at baseline, 1, 3, 6, 9, and 12 months after injection.
  
  
  RESULTS
  One intravitreal injection of ranibizumab was performed in all four eyes. Complete cessation of leakage was documented postintervention in three eyes and partial cessation in one eye, followed by improvement of best corrected VA in one of them. In all eyes, structural changes of the photoreceptor layer were detected in tomography and were responsible for visual loss, which was in most cases, refractory to the applied therapy.
  
  
  CONCLUSIONS
  Use of ranibizumab might be efficient in eliminating leakage activity in the macular region in patients with IPT. Nevertheless, improvement in VA was infrequent. Preexisting early photoreceptor alteration in IPT might render such patients unable to improve VA.
authors.affiliation: 2nd Department of Ophthalmology, Medical School of Athens University, Athens, Greece.
authors.forename: Alexandros
authors.initials: A
authors.lastname: Rouvas
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Malamos
authors.forename: Maria
authors.initials: M
authors.lastname: Douvali
authors.forename: Amalia
authors.initials: A
authors.lastname: Ntouraki
authors.forename: Nikos N
authors.initials: NN
authors.lastname: Markomichelakis
keywords: fluorescein angiography; high-definition optical coherence tomography; idiopathic parafoveal telangiectasis; intravitreal ranibizumab